Jade Biosciences Announces Q4 and Full Year 2025 Results, Unveils Key Pipeline and Financial Updates

San Francisco and Vancouver, BC – March 6, 2026 – Jade Biosciences, Inc. (Nasdaq: JBIO), a clinical-stage biotechnology company dedicated to developing best-in-class therapies for autoimmune diseases, has released its financial results for the fourth quarter and full year ended December 31, 2025, and provided a comprehensive corporate update. The report highlights a robust financial position, significant clinical pipeline progress, and upcoming milestones that could have a material impact on the company’s valuation and investor sentiment.

Key Highlights

• Strong Cash Position: Jade reported \$336.2 million in cash, cash equivalents, and investments as of December 31, 2025, expected to fund operations into the first half of 2028.
• Active Clinical Pipeline:
  • JADE101: Phase 1 healthy volunteer study ongoing, with interim biomarker-rich data expected in Q2 2026. Phase 2 trial in IgA nephropathy (IgAN) patients planned for mid-2026, with preliminary data anticipated in 2027.
  • JADE201: Half-life extended afucosylated anti-BAFF receptor antibody poised to enter first-in-human clinical trial in rheumatoid arthritis in Q2 2026; interim data expected in 2027.
  • JADE301: Third development candidate, an undisclosed antibody for autoimmune diseases, nominated with Phase 1 trials set to begin in the first half of 2027. Further program details expected in H2 2026.
• Recent Financing: Jade completed two private placements in Q4 2025, raising approximately \$180 million, with backing from new and existing leading healthcare investors.
• Financial Performance:
  • R&D expenses were \$93.1 million for FY25, up from \$31.2 million in the prior period, primarily due to expanded personnel, chemistry, manufacturing, controls, and early clinical activities.
  • General and Administrative (G&A) expenses reached \$20.4 million in FY25, up from \$4.3 million, reflecting company growth and infrastructure build-out.
  • Net loss for FY25 was \$127.4 million, compared to \$47.0 million for the prior period, mainly due to increased R&D and G&A expenditures.
  • Shares outstanding as of December 31, 2025, were approximately 70.7 million (includes common stock, pre-funded warrants, and non-voting convertible preferred stock).

Pipeline and Corporate Updates

JADE101: Selective Anti-APRIL Monoclonal Antibody for IgA Nephropathy

• Phase 1 interim results expected in Q2 2026 will inform dose selection for the upcoming Phase 2 trial in IgAN patients.
• Phase 2 trial set for mid-2026, with initial data in 2027.
• Jade is considering opportunities to accelerate development based on Phase 1 findings.

JADE201: Afucosylated Anti-BAFF-R Monoclonal Antibody for Autoimmune Diseases

• First-in-human studies in rheumatoid arthritis patients to commence in Q2 2026; interim data expected in 2027.
• Broad potential for multiple autoimmune indications, given its differentiated mechanism and engineering.

JADE301: Undisclosed Antibody Program for Autoimmune Diseases

• Phase 1 clinical trial to begin in H1 2027.
• Further program details to be disclosed in H2 2026.

Financial Overview

Management Commentary

“We closed 2025 with strong momentum, having initiated the JADE101 Phase 1 healthy volunteer study, advanced JADE201 toward the clinic, and further strengthened our team and balance sheet. With multiple clinical milestones approaching and cash runway expected to extend into the first half of 2028, we are well positioned to execute on our near-term priorities while continuing to build a differentiated pipeline with the goal of delivering best-in-class, disease-modifying autoimmune therapies to patients.”

— Tom Frohlich, CEO

Potential Price-Sensitive Information

• Upcoming clinical data readouts in 2026 and 2027 for JADE101 and JADE201 could have a significant impact on share price, depending on clinical trial outcomes.
• Cash runway extending to H1 2028 reduces near-term financing risk and supports ongoing R&D activities.
• Significant increase in R&D and G&A expenses reflects aggressive pipeline advancement, which, while increasing near-term losses, may position Jade for substantial long-term value creation if clinical milestones are achieved.
• Private placements raising \$180 million in Q4 2025 demonstrate strong investor support and bolster financial stability.
• Planned disclosure of JADE301 details in H2 2026 could serve as a future catalyst for the stock.

About Jade Biosciences

Jade Biosciences is a clinical-stage biotech company focused on developing therapies for autoimmune diseases. Its lead program, JADE101, targets APRIL and is in Phase 1 for IgA nephropathy. JADE201 (anti-BAFF-R) and JADE301 (undisclosed antibody) are in preclinical development. The company was founded based on assets licensed from Paragon Therapeutics, an antibody discovery company backed by Fairmount.

For more information, visit JadeBiosciences.com and follow the company on LinkedIn.

Contact

Jade Biosciences
Priyanka Shah
[email protected]
[email protected]
908-447-6134

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consider their own financial situation before making any investment decisions. The information is based on company filings and may contain forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those projected. The author and publisher accept no liability for actions taken based on this article.

View Jade Biosciences, Inc. Historical chart here